# APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors

Source: https://onco.cc/trials/nct05701306/  
OnCo record `nct05701306` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of APG-115 in neuroblastoma, run by Ascentage Pharma Group Inc., now recruiting.

## Summary

APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors is a phase 1/2 interventional study registered as NCT05701306 by Ascentage Pharma Group Inc., with 100 participants planned, started 2023-02-28 and due to reach its primary completion in 2027-06-01. Interventions recorded: APG-115 and APG-2575.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05701306
- Phase: 1/2
- Setting: A Phase Ib-ⅡClinical Study of APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors
- Sponsor: Ascentage Pharma Group Inc.
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT05701306: https://clinicaltrials.gov/study/NCT05701306

## Connected records

- cancers: [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/)
- companies: [Ascentage Pharma](https://onco.cc/companies/ascentage-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct05701306.json